| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 15 | 2025 | 1002 | 3.950 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 2092 | 3.690 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 121 | 3.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2021 | 760 | 2.910 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2020 | 82 | 2.580 |
Why?
|
| Heart Failure | 12 | 2024 | 2428 | 2.560 |
Why?
|
| Stroke | 7 | 2023 | 1079 | 2.070 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2025 | 303 | 1.970 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 609 | 1.880 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 699 | 1.830 |
Why?
|
| Anticholesteremic Agents | 4 | 2022 | 247 | 1.520 |
Why?
|
| Troponin I | 3 | 2024 | 121 | 1.510 |
Why?
|
| Dyslipidemias | 3 | 2019 | 246 | 1.480 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 75 | 1.450 |
Why?
|
| Coronary Disease | 3 | 2023 | 685 | 1.230 |
Why?
|
| Hypercholesterolemia | 4 | 2020 | 236 | 1.210 |
Why?
|
| Inferior Wall Myocardial Infarction | 2 | 2018 | 8 | 1.170 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 90 | 1.160 |
Why?
|
| Stents | 2 | 2025 | 881 | 1.150 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 191 | 1.140 |
Why?
|
| Lipids | 4 | 2019 | 565 | 1.130 |
Why?
|
| Coronary Angiography | 5 | 2024 | 485 | 1.090 |
Why?
|
| Coronary Artery Disease | 3 | 2025 | 896 | 1.050 |
Why?
|
| Electrocardiography | 4 | 2024 | 996 | 1.040 |
Why?
|
| Risk Factors | 22 | 2025 | 11166 | 0.990 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1068 | 0.970 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 1049 | 0.960 |
Why?
|
| Ultrasonography, Interventional | 2 | 2025 | 207 | 0.950 |
Why?
|
| Multiple Sclerosis | 7 | 2023 | 386 | 0.910 |
Why?
|
| Humans | 78 | 2025 | 133811 | 0.880 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 24 | 0.860 |
Why?
|
| Brain Ischemia | 2 | 2023 | 278 | 0.860 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 41 | 0.840 |
Why?
|
| Myocardium | 3 | 2018 | 924 | 0.830 |
Why?
|
| Aged | 28 | 2025 | 21714 | 0.820 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2023 | 21 | 0.790 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 251 | 0.780 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 58 | 0.780 |
Why?
|
| Dietary Supplements | 3 | 2021 | 490 | 0.750 |
Why?
|
| Risk Assessment | 8 | 2025 | 3746 | 0.730 |
Why?
|
| Galectin 3 | 1 | 2021 | 37 | 0.710 |
Why?
|
| Lipid Regulating Agents | 1 | 2020 | 6 | 0.690 |
Why?
|
| Biomarkers | 9 | 2024 | 3422 | 0.690 |
Why?
|
| Cardiology | 3 | 2021 | 521 | 0.690 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.680 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 343 | 0.670 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 80 | 0.670 |
Why?
|
| Denervation | 1 | 2020 | 29 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 1221 | 0.660 |
Why?
|
| Veterans | 3 | 2021 | 1784 | 0.650 |
Why?
|
| Middle Aged | 25 | 2025 | 29287 | 0.630 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 111 | 0.610 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3869 | 0.610 |
Why?
|
| Eligibility Determination | 1 | 2019 | 38 | 0.610 |
Why?
|
| Troponin T | 4 | 2024 | 295 | 0.600 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 39 | 0.590 |
Why?
|
| Drug Costs | 1 | 2019 | 66 | 0.590 |
Why?
|
| Smoking Cessation | 1 | 2020 | 209 | 0.590 |
Why?
|
| Biological Products | 1 | 2020 | 139 | 0.580 |
Why?
|
| Docosahexaenoic Acids | 1 | 2019 | 68 | 0.580 |
Why?
|
| Incretins | 1 | 2018 | 24 | 0.560 |
Why?
|
| Secondary Prevention | 1 | 2019 | 223 | 0.550 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 144 | 0.550 |
Why?
|
| Anticoagulants | 3 | 2020 | 628 | 0.550 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 385 | 0.540 |
Why?
|
| Treatment Outcome | 12 | 2025 | 13114 | 0.540 |
Why?
|
| Cardiovascular System | 1 | 2018 | 110 | 0.530 |
Why?
|
| Pyrimidines | 1 | 2020 | 420 | 0.530 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 938 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.530 |
Why?
|
| United States | 16 | 2022 | 11760 | 0.510 |
Why?
|
| Pandemics | 2 | 2021 | 1193 | 0.500 |
Why?
|
| Male | 33 | 2025 | 65939 | 0.490 |
Why?
|
| Kidney | 2 | 2020 | 1395 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.460 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 1880 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 395 | 0.460 |
Why?
|
| Peptide Fragments | 3 | 2023 | 828 | 0.450 |
Why?
|
| Hypertension | 2 | 2021 | 1403 | 0.450 |
Why?
|
| Ezetimibe | 3 | 2019 | 98 | 0.450 |
Why?
|
| Female | 30 | 2025 | 71840 | 0.450 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 492 | 0.420 |
Why?
|
| Hospitalization | 2 | 2019 | 1921 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 555 | 0.420 |
Why?
|
| Aged, 80 and over | 9 | 2023 | 7195 | 0.410 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2023 | 42 | 0.390 |
Why?
|
| Blood Pressure | 3 | 2024 | 1411 | 0.380 |
Why?
|
| Sitosterols | 2 | 2009 | 10 | 0.370 |
Why?
|
| Berberine | 2 | 2009 | 10 | 0.370 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2021 | 715 | 0.370 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 107 | 0.360 |
Why?
|
| Glucosides | 3 | 2020 | 48 | 0.350 |
Why?
|
| Tobacco, Smokeless | 2 | 2020 | 14 | 0.340 |
Why?
|
| Benzhydryl Compounds | 3 | 2020 | 68 | 0.340 |
Why?
|
| Dicarboxylic Acids | 3 | 2019 | 34 | 0.340 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1160 | 0.330 |
Why?
|
| Prognosis | 6 | 2025 | 5071 | 0.320 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3107 | 0.310 |
Why?
|
| Europe | 2 | 2020 | 380 | 0.310 |
Why?
|
| Congresses as Topic | 2 | 2020 | 191 | 0.300 |
Why?
|
| Cholesterol | 2 | 2009 | 574 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1420 | 0.290 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 83 | 0.290 |
Why?
|
| Fatty Acids | 3 | 2019 | 366 | 0.290 |
Why?
|
| Triglycerides | 3 | 2022 | 616 | 0.290 |
Why?
|
| Phytosterols | 1 | 2008 | 29 | 0.280 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 300 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 2303 | 0.280 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 721 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2948 | 0.250 |
Why?
|
| Heart Rate | 2 | 2018 | 586 | 0.230 |
Why?
|
| Time Factors | 4 | 2025 | 6554 | 0.230 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 13 | 0.220 |
Why?
|
| Mutation | 1 | 2018 | 6350 | 0.220 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3739 | 0.210 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 162 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 174 | 0.210 |
Why?
|
| Interleukin-18 | 1 | 2023 | 68 | 0.210 |
Why?
|
| Fishes | 1 | 2023 | 42 | 0.210 |
Why?
|
| Biological Phenomena | 1 | 2023 | 3 | 0.200 |
Why?
|
| Postmenopause | 2 | 2020 | 155 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1165 | 0.200 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 569 | 0.200 |
Why?
|
| HLA-DRB1 Chains | 2 | 2013 | 45 | 0.200 |
Why?
|
| HLA-B Antigens | 2 | 2012 | 30 | 0.190 |
Why?
|
| Radial Artery | 1 | 2022 | 30 | 0.190 |
Why?
|
| Adult | 14 | 2025 | 31823 | 0.190 |
Why?
|
| Animals | 8 | 2023 | 36222 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 6602 | 0.190 |
Why?
|
| Phenotype | 4 | 2021 | 4593 | 0.190 |
Why?
|
| Proprotein Convertase 9 | 1 | 2022 | 82 | 0.180 |
Why?
|
| HLA Antigens | 2 | 2021 | 220 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 441 | 0.180 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 51 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 157 | 0.170 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 1485 | 0.170 |
Why?
|
| Tobacco Use | 1 | 2020 | 31 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 470 | 0.170 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 50 | 0.170 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 35 | 0.170 |
Why?
|
| Telecommunications | 1 | 2020 | 22 | 0.170 |
Why?
|
| Vitamin K | 1 | 2020 | 39 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2021 | 51 | 0.170 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 41 | 0.170 |
Why?
|
| Oligonucleotides | 1 | 2020 | 94 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 107 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2019 | 395 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 88 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 72 | 0.160 |
Why?
|
| Echocardiography | 2 | 2023 | 1127 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 453 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2021 | 185 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 30 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 80 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 37 | 0.160 |
Why?
|
| Protective Factors | 1 | 2020 | 91 | 0.160 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 58 | 0.160 |
Why?
|
| Angina Pectoris | 1 | 2019 | 68 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 86 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 26 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2021 | 789 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 147 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 158 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2019 | 49 | 0.150 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2022 | 330 | 0.150 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 18 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 78 | 0.150 |
Why?
|
| RNA Interference | 1 | 2020 | 547 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 205 | 0.150 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 19 | 0.150 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 367 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 342 | 0.150 |
Why?
|
| Monocytes | 1 | 2020 | 346 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 214 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 296 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 41 | 0.140 |
Why?
|
| Young Adult | 4 | 2020 | 9926 | 0.140 |
Why?
|
| Paraplegia | 1 | 2018 | 89 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 121 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 104 | 0.140 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 114 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 244 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 387 | 0.140 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2017 | 47 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1728 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 376 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 176 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 548 | 0.130 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 188 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 505 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 168 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 1323 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 110 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2019 | 910 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 244 | 0.120 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 19 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 779 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 680 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 343 | 0.120 |
Why?
|
| Incidence | 2 | 2025 | 3416 | 0.120 |
Why?
|
| Genotype | 2 | 2021 | 2819 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 20610 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 519 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 542 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 474 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 494 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 545 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2019 | 540 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 237 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 267 | 0.120 |
Why?
|
| Action Potentials | 1 | 2018 | 521 | 0.110 |
Why?
|
| Recurrence | 3 | 2023 | 1470 | 0.110 |
Why?
|
| Patient Selection | 1 | 2019 | 736 | 0.110 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 200 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 681 | 0.110 |
Why?
|
| Testosterone | 1 | 2020 | 624 | 0.110 |
Why?
|
| Aging | 1 | 2022 | 1283 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2018 | 890 | 0.110 |
Why?
|
| Lipoproteins | 2 | 2022 | 192 | 0.110 |
Why?
|
| Macular Degeneration | 1 | 2016 | 127 | 0.110 |
Why?
|
| Alleles | 2 | 2021 | 1724 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 30 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2020 | 719 | 0.100 |
Why?
|
| HLA-DP beta-Chains | 1 | 2012 | 10 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1618 | 0.090 |
Why?
|
| Major Histocompatibility Complex | 1 | 2012 | 53 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 5219 | 0.090 |
Why?
|
| Genome, Human | 3 | 2021 | 1350 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 948 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 31 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5455 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 417 | 0.080 |
Why?
|
| Immunologic Factors | 2 | 2022 | 186 | 0.080 |
Why?
|
| Amino Acids | 1 | 2013 | 685 | 0.080 |
Why?
|
| Prevalence | 3 | 2022 | 2639 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2017 | 3644 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 39 | 0.080 |
Why?
|
| Brain | 2 | 2022 | 3223 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 822 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 33 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 42 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 3506 | 0.080 |
Why?
|
| Child | 2 | 2020 | 25882 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 489 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 295 | 0.070 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1147 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 441 | 0.070 |
Why?
|
| Disease Progression | 2 | 2023 | 2255 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4760 | 0.060 |
Why?
|
| Age Factors | 2 | 2025 | 2987 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 1626 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 4922 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1630 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1036 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1303 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17577 | 0.060 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 10 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 637 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 40 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 14878 | 0.050 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 46 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 105 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 45 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 232 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 356 | 0.040 |
Why?
|
| Rats | 1 | 2008 | 3851 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 4006 | 0.040 |
Why?
|
| Haplotypes | 2 | 2013 | 559 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 52 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 126 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 817 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 203 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 177 | 0.040 |
Why?
|
| Acute Disease | 1 | 2023 | 1185 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 15 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2075 | 0.040 |
Why?
|
| Lisinopril | 1 | 2019 | 23 | 0.040 |
Why?
|
| Amlodipine | 1 | 2019 | 20 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2019 | 63 | 0.040 |
Why?
|
| Metoprolol | 1 | 2019 | 21 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 191 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 87 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 74 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 712 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 397 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 517 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 277 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 527 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2018 | 640 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2017 | 133 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1088 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 316 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 164 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 292 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 731 | 0.030 |
Why?
|
| Metagenomics | 1 | 2017 | 110 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 716 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 410 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 415 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 897 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 333 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 273 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1707 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1853 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 111 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3047 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2013 | 220 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 299 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3144 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 874 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2013 | 198 | 0.020 |
Why?
|
| Disease Resistance | 1 | 2012 | 28 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1166 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 780 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 18936 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2010 | 56 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 52 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 15 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 869 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 239 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 395 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 103 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 464 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 198 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 239 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2009 | 312 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1068 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 1611 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1860 | 0.010 |
Why?
|